La cadena de opciones muestra datos clave de las opciones de acciones de Bicara Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Bicara Therapeutics..

Bicara Therapeutics (NASDAQ:BCAX) Bolsa, Cadena de Opciones

BICARA THERAPEUTICS INC

Bicara Therapeutics

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALVO

BBGI

BCAX

ELTX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TMCI

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

Bicara Therapeutics Inc

Press Releases

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Health Care

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

Earnings

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

General

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Management

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

BBNX

BCYC

BOLD

IMGO

KMTS

MORF

RLAY

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma

AnaptysBio

CareDx

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

ETHZilla

Gyre Therapeutics

Immatics

Inventiva S.A. - American Depository Shares

Inventiva

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals

Keros Therapeutics

Kura Oncology

MeiraGTx Hldgs

Nurix Therapeutics

Organogenesis Holdings

Oruka Therapeutics

Prime Medicine

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Relay Therapeutics

Rezolute

Tango Therapeutics

Tourmaline Bio

Tyra Biosciences

Vir Biotechnology

Zenas BioPharma

HC Wainwright & Co.

Piper Sandler

Wells Fargo

Cantor Fitzgerald

Wedbush

Comments

Bicara Therapeutics

Bicara Therapeutics (BCAX) Opciones

Bicara Therapeutics (NASDAQ:BCAX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL